A review of the carbapenems in clinical use and clinical trials.

Tze S Lo, Justin M Welch, Augusto M Alonto, Eileen A R Vicaldo-Alonto
Author Information
  1. Tze S Lo: Section of Infectious Diseases, Veterans Affairs Medical Center, Fargo, ND, USA. tshienlo@medicine.nodak.edu

Abstract

Despite alarming data showing the ever increasing number of bacteria becoming resistant to different classes of antibiotics through various mechanisms, the carbapenems remain a unique class of antibiotics that possess the broadest spectrum against Gram-positive, Gram-negative, aerobic and anaerobic organisms. However, bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, carry mechanisms that can inactivate the carbapenems. This article gives a review of the carbapenems that are currently in clinical use as well as discusses the new carbapenems that are in clinical trials. These new carbapenems show promising potential to overcome the resistance against the presently existing carbapenems. The present article shows the recent patents using carbapenems as an effective antibiotic.

MeSH Term

Anti-Bacterial Agents
Carbapenems
Clinical Trials as Topic
Drug Design
Drug Interactions
Drug Resistance, Bacterial
Drugs, Investigational
Humans
Molecular Structure
Patents as Topic
Structure-Activity Relationship
Treatment Outcome

Chemicals

Anti-Bacterial Agents
Carbapenems
Drugs, Investigational

Word Cloud

Created with Highcharts 10.0.0carbapenemsclinicalbacteriaantibioticsmechanismsarticlereviewusenewtrialsDespitealarmingdatashowingeverincreasingnumberbecomingresistantdifferentclassesvariousremainuniqueclasspossessbroadestspectrumGram-positiveGram-negativeaerobicanaerobicorganismsHowevermethicillin-resistantStaphylococcusaureusMRSAPseudomonasaeruginosacarrycaninactivategivescurrentlywelldiscussesshowpromisingpotentialovercomeresistancepresentlyexistingpresentshowsrecentpatentsusingeffectiveantibiotic

Similar Articles

Cited By